By contrast, promoting the expansion of adipose tissue though hyperplasia has the potential to redistribute excess lipid between newly differentiated adipocytes with enhanced insulin sensitivity and lipid storage capacity. Thus, improving adipocyte function via MCT1 inhibition-induced hyperplasia may provide a novel therapeutic strategy for obesity and related metabolic disorders. Here, SLC16A1 is linked to metabolic disease.